• 1
    Kapur, S., Remington, G. (2001) Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. Annu Rev Med. 52: 503517.
  • 2
    Fulton, B., Goa, K. L. (1997) Olanzapine: a review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Drugs. 53: 281298.
  • 3
    Schotte, A., Janssen, P. F., Gommeren, W., et al. (1996) Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl). 124: 5773.
  • 4
    Green, B. (1999) Focus on olanzapine. Curr Med Res Opin. 15: 7985.
  • 5
    Hale, A. S. (1997) Olanzapine. Br J Hosp Med. 58: 442445.
  • 6
    Casey, D. E. (1997) The relationship of pharmacology to side effects. J Clin Psychiatry. 58(Suppl 10): 5562.
  • 7
    Baldessarini, R. J., Tarazi, F. I. (2001) Drugs and the treatment of psychiatric disorders. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 10th ed. McGraw-Hill Medical Publishing Division New York; 485520.
  • 8
    Toren, P., Ratner, S., Laor, N., Weizman, A. (2004) Benefit-risk assessment of atypical antipsychotics in the treatment of schizophrenia and comorbid disorders in children and adolescents. Drug Saf. 27: 11351156.
  • 9
    Baptista, T., Beaulieu, S. (2002) Are leptin and cytokines involved in body weight gain during treatment with antipsychotic drugs? Can J Psychiatry. 47: 742749.
  • 10
    Kinon, B. J., Basson, B. R., Gilmore, J. A., Tollefson, G. D. (2001) Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry. 62: 92100.
  • 11
    Murashita, M., Kusumi, I., Inoue, T., et al. (2005) Olanzapine increases plasma ghrelin level in patients with schizophrenia. Psychoneuroendocrinology. 30: 106110.
  • 12
    Gothelf, D., Falk, B., Singer, P., et al. (2002) Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine. Am J Psychiatry. 159: 10551057.
  • 13
    Baptista, T., Zarate, J., Joober, R., et al. (2004) Drug induced weight gain, an impediment to successful pharmacotherapy: focus on antipsychotics. Curr Drug Targets. 5: 279299.
  • 14
    Graham, K. A., Perkins, D. O., Edwards, L. J., et al. (2005) Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis. Am J Psychiatry. 162: 118123.
  • 15
    Haupt, D. W., Luber, A., Maeda, J., et al. (2005) Plasma leptin and adiposity during antipsychotic treatment of schizophrenia. Neuropsychopharmacology. 30: 184191.
  • 16
    Togo, T., Hasegawa, K., Miura, S., et al. (2004) Serum ghrelin concentrations in patients receiving olanzapine or risperidone. Psychopharmacology (Berl). 172: 230232.
  • 17
    Vieta, E., Sanchez-Moreno, J., Goikolea, J. M., et al. (2004) Effects on weight and outcome of long-term olanzapine-topiramate combination treatment in bipolar disorder. J Clin Psychopharmacol. 24: 374378.
  • 18
    Baptista, T., Kin, N. M., Beaulieu, S., de Baptista, E. A. (2002) Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Pharmacopsychiatry. 35: 205219.
  • 19
    Levy, E., Margolese, H. C., Chouinard, G. (2002) Topiramate produced weight loss following olanzapine-induced weight gain in schizophrenia. J Clin Psychiatry. 63: 1045
  • 20
    Dursun, S. M., Devarajan, S. (2000) Clozapine weight gain, plus topiramate weight loss. Can J Psychiatry. 45: 198
  • 21
    Navarro, V., Pons, A., Romero, A., Bernardo, M. (2001) Topiramate for clozapine-induced seizures. Am J Psychiatry. 158: 968969.
  • 22
    Appolinario, J. C., Fontenelle, L. F., Papelbaum, M., Bueno, J. R., Coutinho, W. (2002) Topiramate use in obese patients with binge eating disorder: an open study. Can J Psychiatry. 47: 271273.
  • 23
    Sokoloff, P., Giros, B., Martres, M. P., et al. (1992) Localization and function of the D3 dopamine receptor. Arzneimittelforschung. 42: 224230.
  • 24
    Bello, N. T., Lucas, L. R., Hajnal, A. (2002) Repeated sucrose access influences dopamine D2 receptor density in the striatum. Neuroreport. 13: 15751578.
  • 25
    Fell, M. J., Marshall, K. M., Williams, J., Neill, J. C. (2004) Effects of the atypical antipsychotic olanzapine on reproductive function and weight gain in female rats. J Psychopharmacol. 18: 149155.
  • 26
    Arjona, A. A., Zhang, S. X., Adamson, B., Wurtman, R. J. (2004) An animal model of antipsychotic-induced weight gain. Behav Brain Res. 152: 121127.
  • 27
    Pouzet, B., Mow, T., Kreilgaard, M., Velschow, S. (2003) Chronic treatment with antipsychotics in rats as a model for antipsychotic-induced weight gain in human. Pharmacol Biochem Behav.. 75: 133140.
  • 28
    Goudie, A. J., Smith, J. A., Halford, J. C. (2002) Characterization of olanzapine-induced weight gain in rats. J Psychopharmacol. 16: 291296.
  • 29
    Katz, A., Nambi, S. S., Mather, K., et al. (2000) Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 85: 24022410.
  • 30
    Hajnal, A., Norgren, R. (2001) Accumbens dopamine mechanisms in sucrose intake. Brain Res. 904: 7684.
  • 31
    Wang, G. J., Volkow, N. D., Logan, J., et al. (2001) Brain dopamine and obesity. Lancet 357: 354357.
  • 32
    Wang, G. J., Volkow, N. D., Thanos, P. K., Fowler, J. S. (2004) Similarity between obesity and drug addiction as assessed by neurofunctional imaging: a concept review. J Addict Dis. 23: 3953.
  • 33
    Garnett, W. R. (2000) Clinical pharmacology of topiramate: a review. Epilepsia. 41(Suppl 1): S61S65.
  • 34
    Theisen, F. M., Linden, A., Konig, I. R., et al. (2003) Spectrum of binge eating symptomatology in patients treated with clozapine and olanzapine. J Neural Transm. 110: 111121.
  • 35
    Ebenbichler, C. F., Laimer, M., Eder, U., et al. (2003) Olanzapine induces insulin resistance: results from a prospective study. J Clin Psychiatry. 64: 14361439.
  • 36
    Thornton-Jones, Z., Neill, J. C., Reynolds, G. P. (2002) The atypical antipsychotic olanzapine enhances ingestive behaviour in the rat: a preliminary study. J Psychopharmacol. 16: 3537.
  • 37
    Bodosi, B., Gardi, J., Hajdu, I., et al. (2004) Rhythms of ghrelin, leptin, and sleep in rats: effects of the normal diurnal cycle, restricted feeding, and sleep deprivation. Am J Physiol Regul Integr Comp Physiol. 287: R1071R1079.
  • 38
    Polson, D. A., Thompson, M. P. (2004) Macronutrient composition of the diet differentially affects leptin and adiponutrin mRNA expression in response to meal feeding. J Nutr Biochem. 15: 242246.
  • 39
    Melkersson, K. I., Hulting, A. L. (2001) Insulin and leptin levels in patients with schizophrenia or related psychoses: a comparison between different antipsychotic agents. Psychopharmacology (Berl). 154: 205212.
  • 40
    Melkersson, K. I., Hulting, A. L., Brismar, K. E. (2000) Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J Clin Psychiatry. 61: 742749.
  • 41
    Budman, C. L., Gayer, A. I. (2001) Low blood glucose and olanzapine. Am J Psychiatry. 158: 500501.
  • 42
    Mook, D. G., Dreifuss, S., Keats, P. H. (1986) Satiety for glucose solution in rat: the specificity is postingestive. Physiol Behav. 36: 897901.
  • 43
    Moskowitz, H. R., Kumraiah, V., Sharma, K. N., Jacobs, H. L., Sharma, S. D. (1976) Effects of hunger, satiety and glucose load upon taste intensity and taste hedonics. Physiol Behav. 16: 471475.
  • 44
    Baptista, T., Contreras, Q., Teneud, L., et al. (1998) Mechanism of the neuroleptic-induced obesity in female rats. Prog Neuropsychopharmacol Biol Psychiatry. 22: 187198.
  • 45
    Perrone, J. A., Chabla, J. M., Hallas, B. H., Horowitz, J. M., Torres, G. (2004) Weight loss dynamics during combined fluoxetine and olanzapine treatment. BMC Pharmacol. 4: 27
  • 46
    Hartfield, A. W., Moore, N. A., Clifton, P. G. (2003) Effects of clozapine, olanzapine and haloperidol on the microstructure of ingestive behaviour in the rat. Psychopharmacology (Berl). 167: 115122.
  • 47
    Heil, S. H. (1999) Sex-specific effects of prolactin on food intake by rats. Horm Behav. 35: 4754.
  • 48
    Cooper, G. D., Pickavance, L. C., Wilding, J. P., Halford, J. C., Goudie, A. J. (2005) A parametric analysis of olanzapine-induced weight gain in female rats. Psychopharmacology (Berl). 181: 8089.
  • 49
    Bagnasco, M., Kalra, P. S., Kalra, S. P. (2002) Plasma leptin levels are pulsatile in adult rats: effects of gonadectomy. Neuroendocrinology. 75: 257263.
  • 50
    Landt, M., Gingerich, R. L., Havel, P. J., et al. (1998) Radioimmunoassay of rat leptin: sexual dimorphism reversed from humans. Clin Chem. 44: 565570.
  • 51
    Mulet, T., Pico, C., Oliver, P., Palou, A. (2003) Blood leptin homeostasis: sex-associated differences in circulating leptin levels in rats are independent of tissue leptin expression. Int J Biochem Cell Biol. 35: 104110.
  • 52
    Clegg, D. J., Riedy, C. A., Smith, K. A., Benoit, S. C., Woods, S. C. (2003) Differential sensitivity to central leptin and insulin in male and female rats. Diabetes. 52: 682687.
  • 53
    Baptista, T., Lacruz, A., Paez, X., Hernandez, L., Beaulieu, S. (2002) The antipsychotic drug sulpiride does not affect bodyweight in male rats: is insulin resistance involved? Eur J Pharmacol. 447: 9198.
  • 54
    Baptista, T., Mata, A., Teneud, L., et al. (1993) Effects of long-term administration of clozapine on body weight and food intake in rats. Pharmacol Biochem Behav. 45: 5154.
  • 55
    Casey, D. E., Zorn, S. H. (2001) The pharmacology of weight gain with antipsychotics. J Clin Psychiatry. 62(Suppl 7): 410.
  • 56
    Frankle, W. G., Gil, R., Hackett, E., et al. (2004) Occupancy of dopamine D2 receptors by the atypical antipsychotic drugs risperidone and olanzapine: theoretical implications. Psychopharmacology (Berl). 175: 473480.
  • 57
    Tauscher, J., Hussain, T., Agid, O., et al. (2004) Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics. Am J Psychiatry. 161: 16201625.
  • 58
    Tarazi, F. I., Zhang, K., Baldessarini, R. J. (2001) Long-term effects of olanzapine, risperidone, and quetiapine on dopamine receptor types in regions of rat brain: implications for antipsychotic drug treatment. J Pharmacol Exp Ther. 297: 711717.
  • 59
    Colantuoni, C., Schwenker, J., McCarthy, J., et al. (2001) Excessive sugar intake alters binding to dopamine and mu-opioid receptors in the brain. Neuroreport. 12: 35493552.
  • 60
    Blum, K., Braverman, E. R., Wood, R. C., et al. (1996) Increased prevalence of the Taq I A1 allele of the dopamine receptor gene (DRD2) in obesity with comorbid substance use disorder: a preliminary report. Pharmacogenetics. 6: 297305.
  • 61
    Jenkinson, C. P., Hanson, R., Cray, K., et al. (2000) Association of dopamine D2 receptor polymorphisms Ser311Cys and TaqIA with obesity or type 2 diabetes mellitus in Pima Indians. Int J Obes Relat Metab Disord. 24: 12331238.
  • 62
    Jokinen, M. P., Clarkson, T. B., Prichard, R. W. (1985) Animal models in atherosclerosis research. Exp Mol Pathol. 42: 128.